Bim and Bad mediate imatinib-induced killing of Bcr/Abl(+) leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
Details
Publication Year 2006-10-03,Volume 103,Issue #40,Page 14907-14912
Journal Title
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publication Type
Journal Article
Abstract
Cell killing is a critical pharmacological activity of imatinib to eradicate Bcr/Abl(+) leukemias. We found that imatinib kills Bcr/Abl(+) leukemic cells by triggering the Bcl-2-regulated apoptotic pathway. Imatinib activated several proapoptotic BH3-only proteins: bim and bmf transcription was increased, and both Bim and Bad were activated posttranslationally. Studies using RNAi and cells from gene-targeted mice revealed that Bim plays a major role in imatinib-induced apoptosis of Bcr/Abl(+) leukemic cells and that the combined loss of Bim and Bad abrogates this killing. Loss of Bmf or Puma had no effect. Resistance to imatinib caused by Bcl-2 overexpression or loss of Bim (plus Bad) could be overcome by cotreatment with the BH3 mimetic ABT-737. These results demonstrate that Bim and Bad account for most, perhaps all, imatinib-induced killing of Bcr/Abl(+) leukemic cells and suggest previously undescribed drug combination strategies for cancer therapy.
Publisher
NATL ACAD SCIENCES
Keywords
BH3-ONLY PROTEINS; APOPTOTIC RESPONSES; MYELOID-LEUKEMIA; BCL-2; PHOSPHORYLATION; ACTIVATION; DEATH; DEGRADATION; EXPRESSION; LYMPHOMA
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2006-10-03 12:00:00
An error has occurred. This application may no longer respond until reloaded. Reload 🗙